CLTA and neoplasm: While the opposite was observed in tumor cells, with PRC2 up-regulation leading to down-regulation of PD-L1, it is interesting to see that anti-CLTA-4 immune checkpoint inhibitor therapy is actually improved when given in conjunction with EZH2 therapies [107].